This is a prospective, single-center, open-label study to investigate the diagnostic efficacy of the TruGenome CVD test and its impact on clinical management compared to usual care in individuals with cardiovascular disease. Diagnostic yield and changes of management (CoM) will be assessed both within the WGS group and compared to a contemporaneous, matched (2:1) usual care (UC) group sourced from EHR records.
This trial phase represents an early or specialized stage of clinical development.
Current status: Unknown.
Illumina Inc (ILMN) is the sponsoring company for this trial. BiotechSign currently grades this company F (25/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.